( ferumoxytol had a significantly greate...)Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic,Health

ferumoxytol had a significantly greater mean increase in hemoglobin compared to patients receiving oral iron (ferumoxytol 1.24 +/- 1.25 g/dl vs. oral iron 0.50 +/- 0.98 g/dl, p<0.0001). * Ferumoxytol was more likely to increase baseline hemoglobin by greater than or equal to 1 g/dl compared to oral iron (52.9% of ferumoxytol patients vs. 18.2% of oral iron patients, p<0.0001). * Mean increase in serum ferritin from baseline was significantly greater in the ferumoxytol group compared to the oral iron group at Day 21 (ferumoxytol 416.0 +/- 249.0 ng/ml vs. oral iron 4.3 +/- 48.2 ng/ml, p<0.0001). * Stratifying by ESP use, there was a significantly greater increase in hemoglobin at Day 35 for ferumoxytol compared to oral iron in both patients who were on ESPs and those who were not on ESPs. * In patients on a stable ESP dose, mean hemoglobin increase at Day 35 was 1.66 +/- 1.38 g/dl for ferumoxytol compared to 0.82 +/- 1.28 g/dl for oral iron (p=0.0024). In addition, 66.3% of patients treated with ferumoxytol experienced an increase of +/- 1 g/dl in hemoglobin compared to 35.3% of patients treated with oral iron (p=0.0017). * Similarly, in patients not treated with ESPs, mean hemoglobin increase at Day 35 was 0.93 +/- 1.05 g/dl for ferumoxytol compared to 0.25 +/- 0.56 g/dl for oral iron (p<0.0001). In addition, 43.1% of patients treated with ferumoxytol alone experienced an increase of greater than or equal to 1 g/dl in hemoglobin compared to 4.7% of patients treated with oral iron alone (p<0.0001).

Ferumoxytol was well tolerated with repeated dosing (2 x 510 mg). Adverse events occurred in 55.5% of ferumoxytol patients compared to 59.5% of oral iron patients. Drug-related adverse events occurred in 21.4% of ferumoxytol patients compared to 16.2% o
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer